Evaluation of Prophylactic Heparin Dosage Strategies and Risk Factors for Venous Thromboembolism in the Critically Ill Patient

Notation of prior abstract publication/presentation: The results of this article was presented at the 2018 American College of Clinical Pharmacy Global Conference on Clinical Pharmacy; Seattle, Washington, October 20–23, 2018

Paul M. Reynolds

2018

Scholarcy highlights

  • Notation of prior abstract publication/presentation: The results of this article was presented at the 2018 American College of Clinical Pharmacy Global Conference on Clinical Pharmacy; Seattle, Washington, October 20–23, 2018
  • Multivariable analysis was conducted for VTE risk factors
  • Prophylactic dosing of heparin 3 times/day versus twice/day was not associated with differences in new VTE or safety outcomes
  • Any queries should be directed to the corresponding author for the article

Need more features? Save interactive summary cards to your Scholarcy Library.